CSIMarket Company Name, Ticker, Suppliers, else..
 
Immuron Limited  (NASDAQ: IMRN)
 
Price: $1.1100 $-0.04 -3.478%
Day's High: $1.149999976158142 Week Perf: -2.63 %
Day's Low: $ 1.11 30 Day Perf: 1.83 %
Volume (M): 21,695 52 Wk High: $ 2.39
Volume (M$): $ 0 52 Wk Avg: $1.22
Open: $1.15 52 Wk Low: $0.68



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 12
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Immuron Limited is a biopharmaceutical company that develops and commercializes oral immunotherapeutics for the treatment and/or prevention of various diseases and infections. The company's products are designed to target and improve the gut microbiome, which plays a crucial role in maintaining overall health. Immuron's lead product, Travelan, is a travel vaccine that helps prevent and treat travelers' diarrhea caused by E. coli and other bacteria. Additionally, the company is also involved in developing other immunotherapeutic products for the treatment of C. difficile infection, non-alcoholic steatohepatitis (NASH), and liver diseases. Immuron Limited is headquartered in Melbourne, Australia, and works to advance its products through clinical trials and commercialization partnerships.


   Company Address: Level 3, 62 Lygon Street Victoria 3053
   Company Phone Number: 3 9824 5254   Stock Exchange / Ticker: NASDAQ IMRN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.06%    
AZN   -2.75%    
BMY   -0.7%    
JNJ   -2.63%    
MRK   -1.92%    
PFE        1.75% 
• View Complete Report
   



Partnership

Bridging Innovation with Connection Immuron’s Digital Leap with InvestorHub,

Published Wed, Aug 27 2025 8:51 AM UTC

Building Bridges: Immuron Partners with InvestorHub to Revolutionize Investor Engagement Melbourne, Australia - August 26, 2025 In a strategic move poised to redefine investor relations, Immuron Limited, the biopharmaceutical company known for its innovative approaches in immune health, has announced its new collaboration with InvestorHub. Immuron, listed on both the Aus...
Product Service News

Immuron and Calmino Forge Alliance to Address Irritable Bowel Syndrome in Australia and New Zealand

Published Thu, Mar 13 2025 3:00 PM UTC

In a strategic move to enhance its offerings in the digestive health sector, Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian-based biopharmaceutical company, has announced an exclusive distribution agreement with Calmino for the territories of Australia and New Zealand. This partnership aims to bring ProIBS, an innovative treatment specifically targeting the symptoms...
Product Service News

Immurons Travelan Sales Surge Amidst Financial Hurdles,

Published Tue, Oct 15 2024 10:00 AM UTC

Immuron Limited Reports Sustained Sales Momentum for Travelan amidst Financial Challenges MELBOURNE, Australia, Oct. 15, 2024 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian-based and globally integrated biopharmaceutical company, proudly announced the continued strong sales growth of its over-the-counter immune supplement, Travelan. Designed to combat pathogenic b...
Clinical Study

Navigating the Path to Gut Health Emerging Therapies Targeting Campylobacter and ETEC

Published Fri, Oct 4 2024 10:30 AM UTC

In recent developments that underscore the intersection of innovation and global health challenges, Immuron Limited, an Australian biopharmaceutical company, has announced positive interim results following their collaboration with the US Naval Medical Research Command (NMRC) regarding a new oral therapeutic candidate aimed at infections caused by Campylobacter and Enterotox...
Management Announcement

Immuron Files Pre-IND Application with FDA for IMM-529, Stocks Surge 17.82% in Five Trading Days.

Published Tue, Jul 2 2024 10:00 AM UTC

Immuron Requests Pre-IND Meeting with FDA for IMM-529 and Shares Soar 17.82% in Five Trading Days
Melbourne, Australia - Immuron Limited (ASX: IMC; NASDAQ: IMRN), a leading global biopharmaceutical company based in Australia, is excited to announce the submission of a pre-IND (investigational new drug) application to the United States Food and Drug Administration (FDA) f...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.44
Working Capital Ratio 5.09
Leverage Ratio (MRQ) 0.26
Total Debt to Equity 0.01
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 563,758
Net Income per Employee (TTM) -434,666
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.69

Profitability Ratios Current
Gross Margin (MRQ) 70.44 %
Operating Margin (MRQ) -79 %
Net Margin (MRQ) -77.1 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Immuron Limited's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.